Filing Flows › Regeneron Pharmaceuticals (REGN) › Capital expenditures
Regeneron Pharmaceuticals (REGN) capital expenditures by quarter
Regeneron Pharmaceuticals' capital expenditures were $300M in Q3 2026 (third quarter 2026), +25% from Q2 2026. Over the last 7 quarters it ranged from $201M (Q3 2025) to $300M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $300M | +25% | +49% |
| Q2 2026 | $240M | +4% | +10% |
| Q1 2026 | $231M | -7% | +0.6% |
| Q4 2025 | $249M | +23% | — |
| Q3 2025 | $201M | -8% | — |
| Q2 2025 | $219M | -4% | — |
| Q1 2025 | $229M | — | — |
Q3 2026 at a glance
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is Regeneron Pharmaceuticals' capital expenditures?
Regeneron Pharmaceuticals' capital expenditures were $300M in Q3 2026 (third quarter 2026), +25% from Q2 2026.
How has Regeneron Pharmaceuticals' capital expenditures changed?
Over the last 7 quarters it ranged from $201M (Q3 2025) to $300M (Q3 2026).
Q3 2026 results → · How Regeneron Pharmaceuticals makes money →